Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)

Inclusion Criteria: * Participants must ≥ 18 years of age inclusive, at the time of signing the informed consent. * Participants with severe hemophilia A (FVIII: C\<1%) * PTPs (Previously treated patients) (≥150 ED (Exposure day)) on prophylaxis treatment before enrollment * Participants who are immunocompetent. If human immunodeficiency virus (HIV) positive, cluster of differentiation 4 (CD4)+ lymphocyte count \>200/mm\*3 * Participants who are willing to complete an eDiary * Male participants * Capable of giving signed informed consent Exclusion Criteria: * Any other inherited or acquired bleeding disorder in addition to Hemophilia A. * Platelet count \< 100,000/mm\*3 * Creatinine \> 2x upper limit of normal * AST or ALT \> 5x upper limit of normal (AST: aspartate aminotransferase; ALT: alanine aminotransferase) * The participant has a planned major surgery. * The participant is currently participating in another investigational drug study, or has participated in a clinical study involving an investigational drug within 30 days of signing informed consent or previous treatment in a clinical phase III study with BAY 94-9027 (now marketed as Jivi). * Current evidence (by central laboratory) or history of inhibitor to FVIII with a titer ≥ 0.6 Bethesda unit (BU). * Known hypersensitivity to the drug substance, excipients, or mouse or hamster protein.